Open AccessThe pattern and risk factors associated with adverse drug reactions induced by Reteplase in patients with acute ST-elevation myocardial infarction: The first report from Iranian population
Author(s) -
Naser Aslanabadi,
Naser Safaie,
Faezeh Shadfar,
Mohammad Reza Taban-Sadeghi,
Hossein Feizpour,
Simin Ozar Mashayekhi,
Hadi Hamishehkar,
Naser Khezerlou Aghdam,
Samaneh Dousti,
Hossein Namdar,
Taher EntezariMaleki
Publication year - 2015
Publication title -
journal of research in pharmacy practice
Language(s) - English
Resource type - Journals
eISSN - 2319-9644
pISSN - 2279-042X
DOI - 10.4103/2279-042x.167049
Subject(s) - reteplase , medicine , myocardial infarction , odds ratio , incidence (geometry) , diabetes mellitus , confidence interval , population , logistic regression , thrombolysis , endocrinology , physics , environmental health , optics
Acute myocardial infarction (AMI) is one of the main leading causes of mortality and morbidity. Reteplase is a fibrin-specific thrombolytic which is used in the treatment of AMI. There is a limited number of studies reporting the postmarketing adverse drug reactions (ADRs) induced by reteplase. This study was aimed to examine the reteplase pattern of ADR and its associated risk factors in patients with acute ST-elevation myocardial infarction.